CPRX — Catalyst Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.85bn
- $1.72bn
- $398.20m
- 85
- 43
- 81
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 102 | 119 | 141 | 214 | 398 |
Cost of Revenue | |||||
Gross Profit | 87.5 | 102 | 119 | 180 | 346 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 70.5 | 77.8 | 88.4 | 112 | 311 |
Operating Profit | 31.8 | 41.3 | 52.4 | 102 | 86.8 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 33.4 | 41.9 | 52.7 | 105 | 94.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 31.9 | 75 | 39.5 | 83.1 | 71.4 |
Net Income Before Extraordinary Items | |||||
Net Income | 31.9 | 75 | 39.5 | 83.1 | 71.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 31.9 | 75 | 39.5 | 83.1 | 71.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.301 | 0.706 | 0.366 | 0.746 | 0.628 |